

C&H Generics Limited

Directors' report and financial statements

Year ended 30 April 2025

Registered number: 467808

C&H Generics Limited

Directors' report and financial statements

<i>Contents</i>	<i>Page</i>
Directors and other information	1
Directors' report	2 - 3
Statement of directors' responsibilities in respect of the directors' report and the financial statements	4
Independent auditor's report to the members of C&H Generics Limited	5 - 7
Profit and loss account	8
Balance sheet	9
Statement of changes in equity	10
Notes to the financial statements	11 - 14

C&H Generics Limited

Directors and other information

Directors	Angelo Gatto Aubrey Mulveen
Company secretary	Aubrey Mulveen
Registered office	C/o Chanelle Pharmaceuticals Manufacturing Limited Loughrea Business & Technology Park Dublin Road Loughrea Co. Galway
Independent auditor	KPMG Chartered Accountants Dockgate Dock Road Galway
Bankers	Bank of Ireland 40 Mespil Road Dublin 4 D04 C2N4 Ireland
Solicitor	Arthur Cox Ten Earlsfort Terrace Dublin 2 Ireland
Company registration number	467808

C&H Generics Limited

Directors' report

The directors present their directors' report and financial statements for the year ended 30 April 2025.

Principal activities

The company is a licence holding company.

Results for the year

The results of the company for the year are set out in the profit and loss account on page 8 and in the related notes. The assets, liabilities and financial position of the company are set out in the balance sheet on page 9.

Dividends

The directors do not recommend the payment of a dividend (2024: *€Nil*).

Directors, secretary and their interests

The names of the persons who at any time during the financial year, were directors are set out below. Except where indicated, they served as directors for the entire year:

Aubrey Mulveen
Angelo Gatto (appointed 3 December 2024)
Kara Walsh (resigned 26 August 2025)

On 26 August 2025, Kara Walsh resigned as company secretary and, on the same date, Aubrey Mulveen was appointed in her place.

The directors and secretary who held office at 30 April 2025 had no interests in the shares or debentures or loan stock of, the company or group companies.

Political contributions

The company made no political contributions nor incurred any political expenditure during the year.

Post balance sheet events

There were no material post balance sheet events which would require adjustment to or disclosure in the financial statements.

Accounting records

The directors believe that they have complied with the requirements of Sections 281 to 285 of the Companies Act 2014 with regard to adequate accounting records by employing accounting personnel with appropriate expertise and by providing adequate resources to the financial function. The accounting records of the company are maintained at Loughrea Business & Technology Park, Dublin Road, Loughrea, Co. Galway.

Relevant audit information

The directors believe that they have taken all steps necessary to make themselves aware of any relevant audit information and have established that the company's statutory auditor is aware of that information. In so far as they are aware, there is no relevant audit information of which the company's statutory auditor is unaware.

C&H Generics Limited

Directors' report *(continued)*

Auditor


Pursuant to Section 383(2) of the Companies Act 2014, the auditor, KPMG, Chartered Accountants, will continue in office.

On behalf of the board



Aubrey Mulveen
Director

Angelo Gatto
Director



2025

C&H Generics Limited

Statement of directors' responsibilities in respect of the directors' report and the financial statements

The directors are responsible for preparing the directors' report and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law they have elected to prepare the financial statements in accordance with FRS 102 *The Financial Reporting Standard applicable in the UK and Republic of Ireland*, including Section 1A.

Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company and of its profit or loss for that year.

In preparing the financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- assess the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern; and
- use the going concern basis of accounting unless they either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

The directors are responsible for keeping adequate accounting records which disclose with reasonable accuracy at any time the assets, liabilities, financial position and profit or loss of the company and enable them to ensure that the financial statements are prepared in accordance with the applicable accounting framework and comply with the provisions of the Companies Act 2014. They are responsible for such internal controls as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error, and have general responsibility for taking such steps as are reasonably open to them to safeguard the assets of the company and to prevent and detect fraud and other irregularities. The directors are also responsible for preparing a directors' report that complies with the requirements of the Companies Act 2014.

On behalf of the board



Aubrey Mulveen
Director



Angelo Gatto
Director

17/10/2025



KPMG

Audit
1 Stokes Place
St. Stephen's Green
Dublin 2
D02 DE03
Ireland

Independent auditor's report to the members of C&H Generics Limited

Report on the audit of the financial statements

Opinion

We have audited the financial statements of C&H Generics Limited ("the company") for the year ended 30 April 2025 set out on pages 8 to 14, which comprise the profit and loss account, the balance sheet, the statement of changes in equity and related notes, including the summary of significant accounting policies set out in note 2.

The financial reporting framework that has been applied in their preparation is Irish Law and FRS 102 *The Financial Reporting Standard applicable in the UK and Republic of Ireland* issued in the United Kingdom by the Financial Reporting Council, including its Section 1A.

In our opinion:

- the financial statements give a true and fair view of the assets, liabilities and financial position of the company as at 30 April 2025 and of its result for the year then ended;
- the financial statements have been properly prepared in accordance with FRS 102 *The Financial Reporting Standard applicable in the UK and Republic of Ireland*, including its Section 1A; and
- the financial statements have been properly prepared in accordance with the requirements of the Companies Act 2014.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (Ireland) (ISAs (Ireland)) and applicable law. Our responsibilities under those standards are further described in the *Auditor's responsibilities for the audit of the financial statements* section of our report. We are independent of the company in accordance with ethical requirements that are relevant to our audit of financial statements in Ireland, including the Ethical Standard issued by the Irish Auditing and Accounting Supervisory Authority (IAASA), and we have fulfilled our other ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from the date when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.



Independent auditor's report to the members of C&H Generics Limited *(continued)*

Report on the audit of the financial statements *(continued)*

Other information

The directors are responsible for the other information presented in the Annual Report together with the financial statements. The other information comprises the information included in the directors' report. The financial statements and our auditor's report thereon do not comprise part of the other information. Our opinion on the financial statements does not cover the other information and, accordingly, we do not express an audit opinion or, except as explicitly stated below, any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether, based on our financial statements audit work, the information therein is materially misstated or inconsistent with the financial statements or our audit knowledge. Based solely on that work we have not identified material misstatements in the other information.

Based solely on our work on the other information undertaken during the course of the audit, we report that:

- we have not identified material misstatements in the directors' report;
- in our opinion, the information given in the directors' report is consistent with the financial statements; and
- in our opinion, those parts of the directors' report specified for our review, which does not include sustainability reporting when required by Part 28 of the Companies Act 2014, have been prepared in accordance with the Companies Act 2014.

Our opinions on other matters prescribed by the Companies Act 2014 are unmodified

We have obtained all the information and explanations which we consider necessary for the purposes of our audit.

In our opinion the accounting records of the company were sufficient to permit the financial statements to be readily and properly audited and the financial statements are in agreement with the accounting records.

Matters on which we are required to report by exception

The Companies Act 2014 requires us to report to you if, in our opinion, the disclosures of directors' remuneration and transactions required by Sections 305 to 312 of the Act are not made. We have nothing to report in this regard.

Respective responsibilities and restrictions on use

Responsibilities of directors for the financial statements

As explained more fully in the directors' responsibilities statement set out on page 4, the directors are responsible for: the preparation of the financial statements including being satisfied that they give a true and fair view; such internal control as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error; assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern; and using the going concern basis of accounting unless they either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.



Independent auditor's report to the members of C&H Generics Limited *(continued)*

Respective responsibilities and restrictions on use *(continued)*

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (Ireland) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A fuller description of our responsibilities is provided on IAASA's website at <https://iaasa.ie/publications/description-of-the-auditors-responsibilities-for-the-audit-of-the-financial-statements/>.

The purpose of our audit work and to whom we owe our responsibilities

Our report is made solely to the company's members, as a body, in accordance with Section 391 of the Companies Act 2014. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members, as a body, for our audit work, for this report, or for the opinions we have formed.

Laurence May

for and on behalf of

KPMG

Chartered Accountants, Statutory Audit Firm

Dockgate

Dock Road

Galway

H91 V6RR

21 October 2025

C&H Generics Limited

Profit and loss account for the year ended 30 April 2025

	<i>Note</i>	2025 €	2024 €
Turnover		72,913	13,454
Administrative expenses		(72,913)	(13,454)
		<hr/>	<hr/>
Result before taxation	3	-	-
Taxation		-	-
		<hr/>	<hr/>
Result for the financial year		-	-
		<hr/> <hr/>	<hr/> <hr/>

The company incurred no items of other comprehensive income in the current financial year or prior period. Accordingly, a separate statement of other comprehensive income has not been presented.


C&H Generics Limited

Balance sheet as at 30 April 2025

	Note	2025 €	2024 €
Current assets			
Debtors	5	2	2
Creditors: amounts falling due within one year	6	(11,000)	(11,000)
Net liabilities		<u>(10,998)</u>	<u>(10,998)</u>
Capital and reserves			
Called up share capital presented as equity		2	2
Profit and loss account		(11,000)	(11,000)
Shareholder's deficit		<u>(10,998)</u>	<u>(10,998)</u>

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

On behalf of the board


Aubrey Mulveen
Director


Angelo Gatto
Director

C&H Generics Limited

Statement of changes in equity for the year ended 30 April 2025

	Called up share capital €	Profit and loss account €	Total equity €
Balance at 1 May 2023	2	(11,000)	(10,998)
<i>Total comprehensive income</i> Result for the financial year	-	-	-
	<hr/>	<hr/>	<hr/>
Balance at 30 April 2024	2	(11,000)	(10,998)
<i>Total comprehensive income</i> Result for the financial year	-	-	-
	<hr/>	<hr/>	<hr/>
Balance at 30 April 2025	2	(11,000)	(10,998)
	<hr/> <hr/>	<hr/> <hr/>	<hr/> <hr/>

C&H Generics Limited

Notes

to the financial statements

1 General information

C&H Generics Limited (“the company”) is a private company limited by shares incorporated, domiciled and registered in the Republic of Ireland. The registered office of the company is IDA Industrial Estate, Dublin Road, Loughrea, Co. Galway and its company registration number is 467808.

2 Summary of significant accounting policies

The accounting policies set out below have, unless otherwise stated, been applied consistently to all periods presented in these financial statements.

Basis of preparation

These financial statements were prepared in accordance with Section 1A *Small Entities* of Financial Reporting Standard 102 *The Financial Reporting Standard applicable in the UK and Republic of Ireland* (“FRS 102”). There have been no material departures from that Standard. The functional currency of the company and the presentation currency of these financial statements is Euro.

Measurement convention

The financial statements are prepared on the historical cost basis.

Going concern

The company had net liabilities of €10,998 (2024: €10,998) as at 30 April 2025. The financial statements have been prepared on a going concern basis which assumes that the company will continue in operational existence for the foreseeable future. The validity of this assumption depends on the continued support of the company’s intermediate parent undertaking, Chanelle Holdco 3 Limited.

Chanelle Holdco 3 Limited has confirmed that it will provide the financial support necessary to enable the company to discharge its liabilities as they fall due in the foreseeable future, and at a minimum, for a period of twelve months from the date of approval of these financial statements. On this basis, the directors consider it appropriate to prepare the financial statements on a going concern basis.

The financial statement do not include any adjustments which would be required should it be appropriate to apply the going concern basis of accounting.

Turnover

Turnover comprises a management charge to another group company for its share of expenditure incurred on the administration of the company’s investment holdings.

Intangible assets

Intangible assets comprise of licences acquired by the company and are stated at cost less accumulated amortisation and less accumulated impairment losses. Amortisation is charged to the profit or loss on a straight-line basis over the estimated useful lives of intangible assets. Intangible assets are amortised from the date they are available for use.

C&H Generics Limited

Notes *(continued)*

2 Summary of significant accounting policies *(continued)*

Trade and other debtors/creditors

Trade and other debtors are recognised initially at transaction price plus attributable transaction costs.

Trade and other creditors are recognised initially at transaction price less attributable transaction costs.

Subsequent to initial recognition they are measured at amortised cost using the effective interest method.

Taxation

Tax on the profit or loss for the year comprises current and deferred tax. Tax is recognised in the profit and loss account except to the extent that it relates to items recognised directly in equity or other comprehensive income, in which case it is recognised directly in equity or other comprehensive income.

Current tax is the expected tax payable or receivable on the taxable income or loss for the year, using tax rates enacted or substantively enacted at the balance sheet date, and any adjustment to tax payable in respect of previous years.

Deferred tax is provided on timing differences which arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in the financial statements. Deferred tax is not recognised on permanent differences arising because certain types of income or expense are non-taxable or are disallowable for tax or because certain tax charges or allowances are greater or smaller than the corresponding income or expense.

Deferred tax is measured at the tax rate that is expected to apply to the reversal of the related difference, using tax rates enacted or substantively enacted at the balance sheet date. For investment property that is measured at fair value, deferred tax is provided at the rates and allowances applicable to the sale of the asset/property. Deferred tax balances are not discounted.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Cash flow statement exemption

The company has availed of the exemption contained in Section 1A of FRS 102 and as a result has elected not to prepare a cash flow statement.

C&H Generics Limited

Notes (continued)

2 Summary of significant accounting policies (continued)

Related party transactions

The company discloses transactions with related parties which comprise directors, directors of the holding company and non-wholly owned subsidiaries within the same group. It does not disclose transactions with members of the same group that are wholly owned.

3 Employees and directors' remuneration

The company had no employees during the current or prior financial year. Directors' remuneration is paid by a fellow group company. Management has estimated that €5,371 of total group directors' remuneration could apply to the company (2024: €7,167).

4 Intangible assets	Licences €	
Cost		
Balance at 1 May 2024		9,142

Amortisation and impairment		
Balance at 1 May 2024 and 30 April 2025		(9,142)
		=====
Carrying value		
Balance at 30 April 2025		-
		=====
Balance at 1 May 2024		-
		=====
5 Debtors: amounts falling due within one year	2025	2024
	€	€
Unpaid share capital	2	2
	=====	=====
6 Creditors: amounts falling due within one year	2025	2024
	€	€
Accruals	11,000	11,000
	=====	=====

C&H Generics Limited

Notes (continued)

7 Capital commitments

The company had no capital or other commitments as at 30 April 2025 (2024: €Nil).

8 Related party transactions

The company has availed of the exemption available under Section 33 *Related Party Disclosures* of Financial Reporting Standard 102 from disclosing transactions entered into between members of the group, where the company as a party to the transaction is a wholly owned member.

9 Holding undertaking of smallest group preparing group financial statements

The smallest group in which the results of the company are consolidated is that headed by Herriot Pharma UK Topco Limited, incorporated in England & Wales, with a registered office address at 30 Broadwick Street, London, W1F 8JB, United Kingdom.

10 Post balance sheet events

There were no material post balance sheet events which would require adjustment to or disclosure in the financial statements.

11 Approval of financial statements

The financial statements were approved and authorised for issue by the board of directors on 17/10/2025.

17/10/